Tectonic Therapeutic director granted 10,200 stock options
Tectonic Therapeutic, Inc. director Stefan Vitorovic received a grant of stock options covering 10,200 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Tectonic Therapeutic, Inc. director Stefan Vitorovic received a grant of stock options covering 10,200 shares of common stock. The options have an exercise price of $28.56 per share and expire on June 8, 2036, bringing his option holdings to 10,200 shares.
According to the terms, the award vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, in each case only if he continues providing service to the company through that date.
Insider Trade Summary
Grant/Award: 10,200 shares
Grant/Award
1 txn
Insider
Vitorovic Stefan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 10,200 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,200 contracts (Direct)
Footnotes (1)
- F1. The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.
Key Figures
Options granted: 10,200 options
Exercise price: $28.56 per share
Expiration date: June 8, 2036
+3 more
6 metrics
Options granted
10,200 options
Stock Option (Right to Buy) grant on June 9, 2026
Exercise price
$28.56 per share
Conversion or exercise price for granted options
Expiration date
June 8, 2036
Option expiration if not exercised earlier
Post-grant holdings
10,200 options
Total derivative securities owned following transaction
Transaction code
A (grant/award acquisition)
Indicates compensation-related option grant
Vesting timing
Earliest of June 9, 2027, 2027 meeting, or change in control
Subject to continuous service requirement
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, Change in Control, 2024 Equity Incentive Plan, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Change in Control financial
"or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2024 Equity Incentive Plan financial
"as defined in the Issuer's 2024 Equity Incentive Plan"
continuous service financial
"subject in each case, to the Reporting Person providing continuous service to the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tectonic Therapeutic (TECX) director Stefan Vitorovic report on this Form 4?
Director Stefan Vitorovic reported receiving a grant of stock options for 10,200 shares of Tectonic Therapeutic common stock. These options were awarded at no cost, have an exercise price of $28.56 per share, and represent 10,200 options held after the transaction.
What are the key terms of the 10,200 stock options granted to the TECX director?
The grant consists of options to buy 10,200 shares of common stock at an exercise price of $28.56 per share. The options are scheduled to expire on June 8, 2036, if not exercised earlier, according to the reported terms.
When do Stefan Vitorovic’s Tectonic Therapeutic (TECX) options vest?
The options vest in full on the earliest of June 9, 2027, the date of Tectonic Therapeutic’s 2027 annual meeting of stockholders, or a qualifying change in control, provided he continues to serve the company through the applicable vesting date.
How many Tectonic Therapeutic (TECX) options does the director hold after this grant?
Following this transaction, the director holds options covering 10,200 shares of Tectonic Therapeutic common stock. The filing shows this as the total number of derivative securities beneficially owned after the reported grant on the transaction date.
What type of transaction is reported in this Tectonic Therapeutic (TECX) Form 4?
The Form 4 reports a derivative transaction coded “A,” indicating a grant, award, or other acquisition of stock options. It reflects a compensation-related award rather than an open-market purchase or sale of Tectonic Therapeutic common shares.
What conditions affect vesting of the TECX stock options granted to the director?
Vesting requires continuous service with Tectonic Therapeutic until the earliest of June 9, 2027, the 2027 annual stockholder meeting date, or a defined change in control under the company’s 2024 Equity Incentive Plan, based on the filing’s footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates